NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, Price Target & More

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) released its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $5.08 by $0.41. The biopharmaceutical company had revenue of $1.51 billion for the quarter, compared to analysts' expectations of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 29.92% and a net margin of 23.54%. Regeneron Pharmaceuticals's quarterly revenue was up 14.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.92 EPS. View Regeneron Pharmaceuticals' Earnings History.

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Regeneron Pharmaceuticals.

25 Wall Street analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their predictions range from $290.00 to $593.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $428.8333 in the next twelve months. View Analyst Ratings for Regeneron Pharmaceuticals.

Some companies that are related to Regeneron Pharmaceuticals include Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Shiseido (SSDOY) and ASTELLAS PHARMA/ADR (ALPMY).

Media coverage about REGN stock has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.18 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include SANOFI (95.60%), BlackRock Inc. (5.57%), Loomis Sayles & Co. L P (2.62%), Polen Capital Management LLC (1.32%), Sustainable Growth Advisers LP (0.97%) and American Century Companies Inc. (0.89%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, Sei Investments Co., Franklin Resources Inc., Senzar Asset Management LLC, Prudential Financial Inc., MUFG Securities EMEA plc and Swiss National Bank. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.

REGN stock was acquired by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Old Mutual Global Investors UK Ltd., Rockefeller Capital Management L.P., Summit Trail Advisors LLC, Sustainable Growth Advisers LP, American Century Companies Inc., BB Biotech AG and Natixis Advisors L.P.. View Insider Buying and Selling for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $336.93.

Regeneron Pharmaceuticals has a market capitalization of $33.99 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]